Miniature Transponder Guides Radiation Therapy Procedures
By MedImaging International staff writers Posted on 03 Apr 2016 |
A new implanted transponder can help enhance the precision of radiotherapy (RT) and radiosurgery treatments for cancer by providing real-time, continuous information on tumor position.
The Calypso 17G soft tissue Beacon transponder emits a non-ionizing electromagnetic signal that is tracked in real-time by the Calypso system, guiding treatment beams to target tumors during treatment with medical linear accelerators. The size of a grain of rice, the 17G Beacon has a smaller cross-section area than the current, 14G version, and can be implanted within the soft tissue throughout the body, with the exception of the lung. The Calypso System can then deliver real-time, continuous three dimensional (3D) tumor position information, improving clinician confidence that the prescribed dose has been delivered to the tumor.
Based on the transponder signals, the Calypso System can track even the slightest movement of the tumor without using ionizing radiation, and can precisely target even tumors that exhibit respiratory motion, as the system allows the beam to be gated on only when the tumor is in the planned position. The increased precision can enable treatment margin reduction, protecting healthy tissue and reducing side effects. The Calypso 17G soft tissue Beacon transponder and the Calypso System are products of Varian Medical Systems (Varian, Palo Alto, CA, USA).
“The new 17G implantation device has half the cross-sectional area as the prior 14G technology, increasing patient comfort and improving access to tumors,” said Zachary Collins, MD, section head of interventional radiology at Kansas University Medical Center (Kansas City, USA). “The smaller technology may make the use of Calypso viable in a broader population of liver patients, and may make it possible for interventional radiologists to implant Beacon transponders in the pancreas without an open surgical procedure.”
Organ motion is variable and unpredictable, posing challenges during delivery of external beam RT treatments for cancer. The ability to track target motion in real time during treatment and gate the delivery beam can enable reduction in the margins between the clinical target volume (CTV) and the planning target volume (PTV).
Related Links:
Varian Medical Systems
The Calypso 17G soft tissue Beacon transponder emits a non-ionizing electromagnetic signal that is tracked in real-time by the Calypso system, guiding treatment beams to target tumors during treatment with medical linear accelerators. The size of a grain of rice, the 17G Beacon has a smaller cross-section area than the current, 14G version, and can be implanted within the soft tissue throughout the body, with the exception of the lung. The Calypso System can then deliver real-time, continuous three dimensional (3D) tumor position information, improving clinician confidence that the prescribed dose has been delivered to the tumor.
Based on the transponder signals, the Calypso System can track even the slightest movement of the tumor without using ionizing radiation, and can precisely target even tumors that exhibit respiratory motion, as the system allows the beam to be gated on only when the tumor is in the planned position. The increased precision can enable treatment margin reduction, protecting healthy tissue and reducing side effects. The Calypso 17G soft tissue Beacon transponder and the Calypso System are products of Varian Medical Systems (Varian, Palo Alto, CA, USA).
“The new 17G implantation device has half the cross-sectional area as the prior 14G technology, increasing patient comfort and improving access to tumors,” said Zachary Collins, MD, section head of interventional radiology at Kansas University Medical Center (Kansas City, USA). “The smaller technology may make the use of Calypso viable in a broader population of liver patients, and may make it possible for interventional radiologists to implant Beacon transponders in the pancreas without an open surgical procedure.”
Organ motion is variable and unpredictable, posing challenges during delivery of external beam RT treatments for cancer. The ability to track target motion in real time during treatment and gate the delivery beam can enable reduction in the margins between the clinical target volume (CTV) and the planning target volume (PTV).
Related Links:
Varian Medical Systems
Read the full article by registering today, it's FREE!
Register now for FREE to MedImaging.net and get complete access to news and events that shape the world of Radiology.
- Free digital version edition of Medical Imaging International sent by email on regular basis
- Free print version of Medical Imaging International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of Medical Imaging International in digital format
- Free Medical Imaging International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure